
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Dnmt1 CRISPR Activation Plasmid (h) | sc-400272-ACT | 20 µg | $397.00 | |||
Dnmt1 CRISPR Activation Plasmid (h2) | sc-400272-ACT-2 | 20 µg | $397.00 |
DNMT1 encodes DNA (cytosine-5)-methyltransferase 1 (Dnmt1), the primary maintenance methyltransferase that copies CpG methylation patterns onto nascent DNA strands during S phase. Through interactions with UHRF1, PCNA, and replication-coupled chromatin machinery, Dnmt1 preserves epigenetic memory and supports genome stability, imprinting, and X-chromosome inactivation. DNMT1 activity shapes transcriptional programs via crosstalk with histone modifications and chromatin remodeling, influencing cell identity and differentiation. Dysregulated DNMT1 function and aberrant DNA methylation are linked to oncogenic epigenetic reprogramming, altered DNA repair responses, and neurodevelopmental phenotypes, making it a central target for mechanistic studies of epigenome maintenance.
Dnmt1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous DNMT1 expression without altering the underlying DNA sequence.
Dnmt1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the DNMT1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the DNMT1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Dnmt1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native DNMT1 locus and enabling the study of Dnmt1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Dnmt1 pathway restoration in tumor cells with silenced or reduced DNMT1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.